Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ImmunoPrecise Antibodies Ltd. - Common Stock (NQ:IPA)

0.3434 +0.0034 (+1.00%)
Streaming Delayed Price Updated: 11:00 AM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ImmunoPrecise Antibodies Ltd. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Earnings Scheduled For March 28, 2025
Via Benzinga
A Look Ahead: ImmunoPrecise Antibodies's Earnings Forecast
Via Benzinga
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ImmunoPrecise Antibodies: Q2 Earnings Insights
Via Benzinga
What's going on in today's after hours session
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
What's Going On With ImmunoPrecise Stock Thursday?
ImmunoPrecise announced a partnership with a biotechnology giant to develop ADCs and bispecific antibodies for the treatment of cancer. 
Via Benzinga
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
These stocks are moving in today's pre-market session
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Announces Key Leadership Changes
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
What's Going On With ImmunoPrecise Antibodies Stock Wednesday?
Immunoprecise shares closed higher on Wednesday after the company announced it developed a new class of GLP-1 therapies. 
Via Benzinga
Trump’s “Stargate AI” Healthcare/Medical Watch: CSDX, IPA, MGX, CDIO
Via AB Newswire
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
Via Benzinga
Exposures Fossil Fuels
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings
Via Benzinga
US Stocks Higher; Netflix Profit Beats Estimates
Via Benzinga
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA Announces Resignation of Chief Financial Officer
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Present at The Microcap Conference 2025
Via ACCESSWIRE
IPA to Present at The Microcap Conference 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Earnings Scheduled For December 10, 2024
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.